{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:07:27Z","timestamp":1791209247985,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T00:00:00Z","timestamp":1103500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Reliable predictors of metastatic involvement would enable a better selection of candidate patients for sentinel lymph node biopsy (SLNB) and possibly allow identification of patients with such a low risk of axillary sentinel lymph node (SLN) involvement to be even spared SLNB.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors evaluated 4351 consecutive patients surgically treated for breast carcinoma who also underwent SLNB. Clinicopathologic features significantly associated with SLN metastases by univariate analysis were included in a multivariate model.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>By multivariate analysis, the prevalence of SLN metastases was associated directly with tumor size, multifocality, and with the occurrence of peritumoral vascular invasion (PVI; all <jats:italic>P<\/jats:italic> &lt; 0.0001), and was associated inversely with a favorable histotype (<jats:italic>P<\/jats:italic> = 0.0007) and lack of progesterone receptors (<jats:italic>P<\/jats:italic> = 0.004). A predictive model based on the features more closely associated with SLN status documented that the patients with a favorable tumor type \u2264 1 cm in size and without PVI (<jats:italic>n<\/jats:italic> = 178 [4% of the population]) had the lowest risk of SLN metastases (9.5%) whereas patients with tumors &gt; 2 cm and with PVI (<jats:italic>n<\/jats:italic> = 250 [5.7% of the population]) had the highest risk (77.2%) of SLN involvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Tumor size and PVI emerged as the most powerful independent predictors of SLN metastases. Although no combination of features identified patients with a &lt; 9.5% risk of SLN metastases, the current data may be used to tailor the management of patients with breast carcinoma with the aim of minimizing as much as possible the diagnostic and therapeutic procedures, thus improving the quality of life of the patients without any adverse effect on their survival rates. Cancer 2005 \u00a9 2004 American Cancer Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20809","type":"journal-article","created":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T11:49:42Z","timestamp":1103543382000},"page":"492-500","source":"Crossref","is-referenced-by-count":202,"title":["Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution"],"prefix":"10.1002","volume":"103","author":[{"given":"Giuseppe","family":"Viale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Zurrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Mazzarol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,20]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"528","article-title":"Ten year follow\u2010up results of patients with carcinoma of the breast in a co\u2010operative clinical trial evaluating surgical adjuvant chemotherapy","volume":"140","author":"Fisher B","year":"1975","journal-title":"Surg Gynecol Obstet."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1239"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0140-6736(92)90997-H","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1992","journal-title":"Lancet."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-1433.2001.02266.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.0.CO;2-Q"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10539"},{"key":"e_1_2_5_10_2","first-page":"700","article-title":"Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability","volume":"180","author":"Silverstein MJ","year":"1995","journal-title":"J Am Coll Surg."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<948::AID-CNCR21>3.0.CO;2-U"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-001-0003-x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1511::AID-CNCR18>3.0.CO;2-D"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199911000-00012"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940115)73:2<350::AID-CNCR2820730219>3.0.CO;2-5"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869409121769"},{"key":"e_1_2_5_19_2","first-page":"185","article-title":"Incidence and predictors of axillary metastasis in T1 carcinoma of the breast","volume":"183","author":"Giuliano AE","year":"1996","journal-title":"J Am Coll Surg."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806495"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199705)65:1<34::AID-JSO7>3.0.CO;2-P"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1054\/brst.2000.0220"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.23.1771"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11880"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.4.368"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012782"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2433::AID-CNCR18>3.0.CO;2-3"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010915)92:6<1378::AID-CNCR1460>3.0.CO;2-Y"},{"key":"e_1_2_5_29_2","volume-title":"Histological typing of breast tumors","author":"World Health Organization","year":"1981"},{"key":"e_1_2_5_30_2","series-title":"Atlas of tumor pathology. 3rd series","first-page":"157","author":"Rosen PP","year":"1993"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"e_1_2_5_32_2","series-title":"Atlas of tumor pathology. 3rd series","first-page":"161","author":"Rosen PP","year":"1993"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01004-0"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.1983"},{"key":"e_1_2_5_35_2","volume-title":"Classification of malignant tumours","author":"Sobin LH","year":"2002"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20809","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:33:31Z","timestamp":1760272411000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,20]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1002\/cncr.20809"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20809","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,20]]}}}